Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

NCT03051217 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT03051217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03051217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 2/3
Overall status
Completed
Start date
February 21, 2017
Completion date
January 16, 2019
Enrollment
127 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis and erythrodermic psoriasis, moderate to severe psoriasis